27% growth in prescriptions dispensed over prior quarter; 147% growth over comparable quarter in 2022. 5 consecutive quarters of double-digit growth. Click here to learn more ›

Safety and Efficacy of Bremelanotide for HSDD in Women: RECONNECT Study Open-Label Extension Phase Results

Leave a Reply

Scroll to Top